证券代码：002653 证券简称：海思科 公告编号：2025-086 海思科医药集团股份有限公司 关于控股股东之一致行动人股份减持计划的 预披露公告 股东申萍保证向公司提供的信息披露内容的真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信 息一致。 特别提示： 截止本公告披露日，海思科医药集团股份有限公司（以下简称"公司"）控 股股东之一致行动人申萍女士（控股股东王俊民之配偶）持有公司股份 49,625,894 股，占公司总股本比例 4.43%。 申萍计划自本公告披露之日起十五个交易日后的三个月内，通过大宗交易或 集中竞价方式减持公司股份合计不超过 10,373,400 股，减持比例合计不超过公 司总股本的 0.926%。 近日，公司收到控股股东之一致行动人申萍女士《关于减持公司 股份计划的告知函》，具体情况如下： | 一、本次减持主体及其一致行动人的持股情况 | | --- | | 股东名称 | 持有股份数量（股） | 占公司总股本比例(%) | | --- | --- | --- | | 申萍 | 49,625,894 | 4.43 | | ...

海思科（002653）公告，公司控股股东之一致行动人申萍女士计划减持不超过1037.34万股，占公司总 股本的0.926%。申萍目前持有公司股份4962.59万股，占公司总股本4.43%。减持原因为个人资金需求， 计划在公告披露后十五个交易日内通过大宗交易或集中竞价方式进行。减持价格将根据市场价格确定。 本次减持符合相关法律法规，不会导致公司控制权变更或影响公司治理结构。公司将监督减持计划的合 规实施，并提醒投资者注意风险。 ...

Group 1 - The core viewpoint of the article highlights that innovative drugs have become a key source of returns for public funds in 2023, with the Hong Kong stock market's innovative drug index surging by 93.94% as of July 21 [1] - A significant number of funds have reported exceptional performance, with six funds achieving over 100% returns, all heavily invested in innovative drugs [2][3] - The article emphasizes that the majority of funds with returns exceeding 80% are either actively or passively invested in the innovative drug sector [3] Group 2 - The pharmaceutical industry has faced a downturn since 2021, with the pharmaceutical and biotechnology index dropping over 40.19% and the Hong Kong innovative drug index declining by 59.24% over four years [5] - Despite the previous downturn, many funds have recovered losses from 2024 and generated substantial returns due to the recent surge in innovative drugs [6] - The article suggests that the current market rally may only be a temporary boost for thematic funds, and it is essential to evaluate long-term performance during previous downturns [7][8] Group 3 - The article provides detailed performance data of various funds, highlighting the returns of specific funds managed by notable fund managers, such as Zhang Wei and Jin Xiaofei, who have achieved significant returns through strategic investments in innovative drugs [11][37] - Zhang Wei's management of the Huatai-PineBridge Hong Kong Advantage Fund has yielded a return of 138.23% since its inception, while Jin Xiaofei's Penghua Medical Technology Fund has achieved a return of 260.27% since he took over [11][37] - The article discusses the investment strategies of these fund managers, focusing on their ability to identify undervalued innovative drug companies and their proactive adjustments to market conditions [15][56] Group 4 - The article mentions specific innovative drug companies that have performed well, such as Bai Li Tianheng and Hai Si Ke, which have seen significant stock price increases due to successful transitions from generic to innovative drug companies [24][63] - It highlights the importance of understanding the competitive landscape and long-term industry trends when investing in innovative drugs, as emphasized by fund managers like Zhao Wei [56][58] - The article concludes with a positive outlook for the innovative drug sector, suggesting that supportive policies and market conditions may lead to a recovery and growth in the coming years [34][49]

Group 1 - The core point of the article highlights the performance and holdings of the ICBC Frontier Medical Stock A fund, which has a recent net value of 3.3810 yuan, reflecting a decline of 1.11% [1] - The fund has achieved a return of 12.70% over the past month, ranking 117 out of 717 in its category; a return of 29.84% over the past six months, ranking 54 out of 704; and a year-to-date return of 28.51%, ranking 62 out of 702 [1] - The top ten holdings of the fund account for a total of 59.44%, with significant positions in companies such as Heng Rui Pharmaceutical (9.51%), Kelun Pharmaceutical (9.16%), and Xin Li Tai (6.70%) [1] Group 2 - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, and as of June 30, 2025, it has a total scale of 9.33 billion yuan, managed by fund manager Zhao Bei [1] - Zhao Bei holds a master's degree and has extensive experience in the investment management field, having worked in various roles since joining ICBC Credit Suisse in 2010 [2]

Core Viewpoint - Recently, Haisco Pharmaceutical Group Co., Ltd. announced that the Shenzhen Stock Exchange has accepted its application for a private placement of shares, aiming to raise up to 1.365 billion yuan for new drug research and development and to supplement working capital [1] Company Overview - Haisco is a diversified and specialized pharmaceutical group engaged in new drug research and development, manufacturing, and marketing, with a product portfolio covering multiple segments including anesthesia, parenteral nutrition, anti-tumor, and cardiovascular drugs, among others [3] - The company has over 40 products, including four Class 1 new drugs that have been approved for market, with many others being the first or sole generic versions in China [3] Strategic Transformation - Haisco is undergoing a rapid transformation from focusing on "innovative generics" to a "combination of generics and innovation" due to the impact of generic drug procurement policies [3][4] - The proportion of revenue from generic drugs has decreased from over 80% in 2019 to below 60% in 2024, while the revenue from innovative drugs is expected to exceed 40% by 2025 [4][5] Financial Performance - In 2024, Haisco achieved a revenue of 3.721 billion yuan, a year-on-year increase of 10.92%, and a net profit of 396 million yuan, up 34% year-on-year [5] - Following the release of the annual report, the company's stock price hit the limit up, and its market capitalization exceeded 50 billion yuan for the first time, reflecting market recognition of its innovative drug transformation strategy [5] Funding Needs - The innovative drug research and development process is characterized by long cycles, high investment, and low success rates, leading to significant funding needs for Haisco [6] - The company reported a total R&D investment of 1.589 billion yuan from 2022 to 2024, with 624 million yuan allocated in 2024, marking a 20.7% increase year-on-year [6] Future Plans - Haisco plans to use the raised funds for the research and development of several innovative drugs, including HSK31679 for non-alcoholic fatty liver disease and HSK31858 for respiratory diseases, among others [6] - The company aims to enhance its R&D investment, accelerate clinical trials, and improve the efficiency of drug registration processes, thereby expanding its product line and creating new profit growth points for sustainable development [6]

Core Viewpoint - Recently, Haisco Pharmaceutical Group Co., Ltd. announced that the Shenzhen Stock Exchange has accepted its application for a private placement of shares, aiming to raise up to 1.365 billion yuan for new drug research and development and to supplement working capital [1]. Group 1: Company Overview - Haisco is a diversified and specialized pharmaceutical group engaged in new drug research and development, manufacturing, and marketing, with over 40 product varieties covering multiple therapeutic areas including anesthesia, parenteral nutrition, antiemetics, and antibiotics [4]. - The company has four first-class new drugs approved for market, with many other products being the first or exclusive generics in China [4]. Group 2: Strategic Transformation - Haisco is undergoing a rapid transformation from focusing on "innovative generics" to a "combination of generics and innovation" due to the impact of generic drug procurement [5]. - The number of innovative drug projects has increased to 26 in 2024, while only one generic drug application was submitted during the same year [6]. Group 3: Financial Performance - In 2024, Haisco achieved a revenue of 3.721 billion yuan, a year-on-year increase of 10.92%, and a net profit of 396 million yuan, up 34% year-on-year [8]. - The company's stock price hit a ceiling on the day of the annual report release, with its market capitalization exceeding 50 billion yuan for the first time, reflecting market recognition of its innovative drug transformation strategy [8]. Group 4: Funding Needs - The innovative drug research and development process is characterized by long cycles, high investment, and low success rates, leading to significant funding needs for Haisco [10]. - The total R&D investment from 2022 to 2024 reached 1.589 billion yuan, with 624 million yuan allocated in 2024 alone, marking a 20.7% increase [10]. - Haisco has acknowledged the ongoing substantial R&D expenditures and the resulting financial pressure, with cash reserves of 807 million yuan as of Q3 2024 [12].

证券代码：002653 证券简称：海思科 公告编号：2025-085 海思科医药集团股份有限公司 关于创新药 HSK47388 片获得 FDA 同意开展临床试验的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）于近日收到 美国食品药品监督管理局（以下简称"FDA"）的 Study May Proceed Letter，根据 FDA 相关规定，经审查，公司 2025年5 月递交的 HSK47388 片临床试验申请符合药品注册的有关要求，同意本品开展临床试验。 一、 研发项目简介 1 据该项目的后续进展及时履行信息披露义务。 特此公告。 海思科医药集团股份有限公司董事会 2025 年 7 月 16 日 2 HSK47388片是公司自主研发的口服、强效、高选择性的药物，拟 用于自身免疫疾病的治疗。临床前研究结果显示，HSK47388可以剂量 依赖地抑制大鼠炎症反应，同时也表现出了良好的耐受性和较大的安 全窗，是一款极具开发潜力的药物，有望为自身免疫疾病患者提供一 种新的治疗选择。 HSK47388片在国内的IND申 ...

Group 1 - The medical health ETF Taikang (159760) has seen a 0.17% increase, marking its fifth consecutive rise, while the index it tracks, the National Certificate Public Health and Medical Health Index (980016), rose by 0.13% [1] - As of July 14, the latest scale of the medical health ETF Taikang reached 82.4979 million yuan, a new high in nearly three months [2] - The medical device sector is expected to experience a performance turning point, driven by policies such as the old-for-new program and the gradual clearance of channel inventory [2] Group 2 - The top ten weighted stocks in the National Certificate Public Health and Medical Health Index account for 51.67% of the index, with leading companies including WuXi AppTec (603259) and Hengrui Medicine (600276) [3] - The CDMO sector has rebounded, with WuXi AppTec expected to see significant growth in revenue and profit by mid-2025, indicating strong global market demand [2] - The innovation drug industry chain is anticipated to enter a new upward cycle, supported by an improving domestic investment environment and active financing activities [2]

Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology sector, with a focus on innovative drug companies [2][3]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.82%, outperforming the CSI 300 index (0.82%) and the Wind All A index (1.71%). The market is currently focused on the expectations surrounding semi-annual reports and business development (BD) activities [8][9]. - The launch of the 2025 National Basic Medical Insurance and Commercial Health Insurance innovative drug directory is a significant development. This directory will include high-innovation drugs that provide substantial clinical value and patient benefits, which are not covered by basic medical insurance but recommended for commercial health insurance [3][13]. - The report highlights the importance of the commercial health insurance sector in the payment for innovative drugs, suggesting that the accessibility of high-priced innovative drugs is expected to improve, particularly in the areas of cell and gene therapy [3][13]. Market Weekly Review - The medical research outsourcing sector led the gains with a 9.29% increase, primarily driven by WuXi AppTec's positive semi-annual report announcement. Conversely, offline pharmacies and other biological products experienced declines of -1.29% and -1.55%, respectively [8][9]. - Notable stock performances included Frontier Biotech-U (41.4%), Mediso (38.9%), and Lianhuan Pharmaceutical (38.6%) leading the gains, while ST Unimed (-18.5%), Shenzhou Cell-U (-13.4%), and Shutai Shen (-11.6%) faced significant losses [11][12]. Industry News and Key Company Announcements - The report outlines several key industry events, including the approval of innovative drugs and strategic partnerships among major pharmaceutical companies, which are expected to enhance their market positions and product offerings [13][16][17]. - The report also mentions significant financial forecasts from various companies, indicating strong growth potential in the sector, with some companies projecting net profit increases of over 100% year-on-year [17][18].

证券代码：002653 证券简称：海思科 公告编号：2025-084 海思科医药集团股份有限公司 关于变更保荐机构后 重新签署募集资金三方监管协议的公告 公司于 2025 年 1 月 3 日召开第五届董事会第二十一次会议、第 五届监事会第十一次会议，审议通过了《关于募集资金投资项目整体 结项及节余资金后续安排的议案》，业经 2025 年 1 月 15 日召开的 2025 年第一次临时股东大会审议通过。变更后的募集资金投资项目 情况如下： "盐酸乙酰左卡尼汀片的中国上市后再评价项目"节余募集资金 1,641.52 万元用于永久补充流动资金；"长效口服降血糖新药 HSK- 7653 的中国Ⅲ期临床研究及上市注册项目"中部分节余募集资金 5301.75 万元用于"新型外周神经痛治疗药物 HSK16149 胶囊（中文 通用名：苯磺酸克利加巴林胶囊）的中国Ⅲ期临床研究及上市注册项 目"；剩余的节余募集资金将根据自身发展规划及实际生产经营需求， 2 围绕主业、谨慎论证、合理规划安排使用，尽快寻找新的与主营业务 相关的项目进行投资。 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大 ...